All In Biotech

Drug Trial Radar · NCT07154706

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

A Phase 3 Multicenter Double-blind Randomized Study of Taletrectinib Versus Placebo in Patients With ROS1-Fusion Positive Stage IB-IIIA Non-Small Cell Lung Cancer Who Have Undergone Complete Tumor Resection

Last checked: Nov 20, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Aug 21, 2025

Primary completion

Aug 30, 2030

Study completion Aug 30, 2033

Sponsor

Lead sponsor
Nuvation Bio Inc.Industry
Sponsor type
Industry
First posted
Sep 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this phase 3 multicenter double-blind randomized study is to assess the use of taletrectinib in the early-stage non-small cell lung cancer (NSCLC). The study compares taletrectinib (study drug) versus placebo (sugar pill) in patients with ROS1-fusion positive stage IB, II, IIIA NSCLC. The study will evaluate if taletrectinib is better than placebo at preventing the participant's disease from coming back after the participant's lung tumor was removed.

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Interventions

  • TaletrectinibDrug

    Intervention Label: Taletrectinib Intervention Name: Taletrectinib Dosage Formulation: Capsule Unit Dose Strength(s): 200 mg Dosage Level (s): 400 mg QD Route of Administration: Oral Use: Experimental IMP and NIMP/AxMP : IMP Former Name(s) or Alias(es): AB-106.

  • PlaceboDrug

    Intervention Label: Placebo Intervention Name: Placebo Type: Drug Dosage Formulation: Capsule Unit Dose Strength(s): 200 mg Dosage Level(s): 400 mg QD Route of Administration: Oral Use: Placebo Comparator IMP and NIMP/AxMP: IMP Former Name(s) or Alias(es): Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Outcome Measure: To compare the efficacy of taletrectinib with that of placebo, as measured by disease-free survival (DFS) by investigator assessment.Time frame: Time Frame: Up to approximately 5 years after the first patient is randomized (maximum follow-up of 70 months).

Locations

33 sites in 3 countries. Site status is shown where the registry gives one.

  • UCLA

    Los Angeles, California · Recruiting

  • UCI Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • Georgetown University Medical Cener (GUMC)

    Washington D.C., District of Columbia · Recruiting

  • Advent Health

    Orlando, Florida · Recruiting

  • Saint Alphonsus Health System

    Boise, Idaho · Recruiting

  • Tulane Cancer Center

    New Orleans, Louisiana · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Sarah Cannon Research Institute (SCRI) - Texas Oncology-Central South

    Austin, Texas · Recruiting

  • MD Anderson

    Houston, Texas · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • Princess Margaret Cancer Centre-University Health Network

    Toronto, Ontario, Canada · Recruiting

  • McGill University

    Montreal, Quebec, Canada · Recruiting

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China · Recruiting

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangzhou, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

  • Tongji Hospital Tongji Medical College of HUST

    Wuhan, Hubei, China · Recruiting

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Nantong Tumor Hospital

    Nantong, Jiangsu, China · Recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, China · Recruiting

  • Cancer Hospital of Shandong First Medical University

    Jinan, Shandong, China · Recruiting

  • Linyi Cancer Hospital

    Linyi, Shandong, China · Recruiting

  • Zhongshan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • Tianjin Chest Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.